# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Scotiabank analyst Sung Ji Nam initiates coverage on Biodesix (NASDAQ:BDSX) with a Sector Outperform rating and announces Pr...
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 1...
Craig-Hallum analyst Bill Bonello initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target ...
TD Cowen analyst Dan Brennan initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $2.8.
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 41.67...
Lake Street initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $3.
These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical val...